TrialBlood2025
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.
Jill Corre et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
14 papers cite it
this paperpooled ittrialcites it